10 results on '"Schoepfer, Alain M."'
Search Results
2. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort
- Author
-
Godat, Sébastien, Fournier, Nicolas, Safroneeva, Ekaterina, Juillerat, Pascal, Nydegger, Andreas, Straumann, Alex, Vavricka, Stephan, Biedermann, Luc, Greuter, Thomas, Fraga, Montserrat, Abdelrahman, Karim, Hahnloser, Dieter, Sauter, Bernhard, Rogler, Gerhard, Michetti, Pierre, Schoepfer, Alain M, Swiss IBD Cohort Study Group, Godat, Sébastien, Fournier, Nicolas, Safroneeva, Ekaterina, Juillerat, Pascal, Nydegger, Andreas, Straumann, Alex, Vavricka, Stephan, Biedermann, Luc, Greuter, Thomas, Fraga, Montserrat, Abdelrahman, Karim, Hahnloser, Dieter, Sauter, Bernhard, Rogler, Gerhard, Michetti, Pierre, Schoepfer, Alain M, and Swiss IBD Cohort Study Group
- Abstract
BACKGROUND AND AIM Systematic analyses of inflammatory bowel disease (IBD) drug-related side effects necessitating treatment cessation in large cohorts of patients with IBD are scarce. We aimed to assess the frequency and type of drug-related side effects requiring drug cessation in patients included in the Swiss IBD Cohort. PATIENTS AND METHODS A retrospective review was performed of data from the Swiss IBD Cohort physician questionnaires documenting a treatment cessation for the following drug categories: aminosalicylates, topical and systemic steroids, thiopurines, methotrexate, tumor necrosis factor-antagonists, and calcineurin inhibitors (tacrolimus, cyclosporine). RESULTS A total of 3192 patients were analyzed, of whom 1792 (56.1%) had Crohn's disease, 1322 (41.4%) had ulcerative colitis, and 78 (2.5%) had IBD unclassified. Of 3138 patients treated with IBD drugs, 2129 (67.8%) presented with one or several drug-related side effects necessitating drug cessation. We found a significant positive correlation between the number of concomitantly administered IBD drugs and the occurrence of side effects requiring drug cessation (P<0.001). Logistic regression modeling identified Crohn's disease diagnosis [odds ratio (OR)=1.361, P=0.017], presence of extraintestinal manifestations (OR=2.262, P<0.001), IBD-related surgery (OR=1.419, P=0.006), and the increasing number of concomitantly used IBD drugs [OR=2.007 (P<0.001) for two concomitantly used IBD drugs; OR=3.225 (P<0.001) for at least three concomitantly used IBD drugs] to be associated significantly with the occurrence of IBD drug-related adverse events that necessitated treatment cessation. CONCLUSION Physicians should keep in mind that the number of concomitantly administered IBD drugs is the main risk factor for drug-related adverse events necessitating treatment cessation.
- Published
- 2018
3. Celiac disease is misdiagnosed based on serology only in a substantial proportion of patients
- Author
-
Vavricka, Stephan R, Stelzer, Teresa, Lattmann, Jaqueline, Stotz, Matthias, Lehmann, Romina, Zeitz, Jonas, Scharl, Michael, Misselwitz, Benjamin, Pohl, Daniel, Fried, Michael, Tutuian, Radu, Fasano, Alessio, Schoepfer, Alain M, Rogler, Gerhard, Biedermann, Luc, Greuter, Thomas, Vavricka, Stephan R, Stelzer, Teresa, Lattmann, Jaqueline, Stotz, Matthias, Lehmann, Romina, Zeitz, Jonas, Scharl, Michael, Misselwitz, Benjamin, Pohl, Daniel, Fried, Michael, Tutuian, Radu, Fasano, Alessio, Schoepfer, Alain M, Rogler, Gerhard, Biedermann, Luc, and Greuter, Thomas
- Abstract
BACKGROUND Although the diagnostic process in celiac disease (CeD) has been addressed in several international guidelines, little is known about the actual proceeding in current clinical practice. This study investigated the initial presentation, the diagnostic process, follow-up evaluations, and adherence to a gluten-free diet in CeD patients in a real-life setting in Switzerland from a patient's perspective. METHODS We performed a large patient survey among unselected CeD patients in Switzerland. RESULTS A total of 1689 patients were analyzed. The vast majority complained of both gastrointestinal and nonspecific symptoms (71.5%), whereas 1.8% reported an asymptomatic disease course. A total of 35.8% CeD patients were diagnosed by a nongastroenterologist. The diagnostic process differed between nongastroenterologists and gastroenterologists, with the latter more often using duodenal biopsy alone or in combination with serology (94.7% vs. 63.0%) and nongastroenterologists more frequently establishing the diagnosis without endoscopy (37.0% vs. 5.3%, P<0.001). Follow-up serology after 6 months was performed only in half of all patients (49.4%), whereas 69.9% had at least 1 follow-up serology within the first year after diet initiation. About 39.7% had a follow-up endoscopy with duodenal biopsies (after a median of 12 mo; range, 1 to 600 mo). The likelihood of receiving any follow-up examination was higher in patients initially diagnosed by a gastroenterologist. CONCLUSIONS A significant proportion of CeD patients are diagnosed by nongastroenterologists. Under the diagnostic lead of the latter, more than a third of the patients receive their diagnosis on the basis of a positive serology and/or genetics only, in evident violation of current diagnostic guidelines, which may lead to an overdiagnosis of this entity.
- Published
- 2018
4. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up
- Author
-
Fraga, Montserrat, Fournier, Nicolas, Safroneeva, Ekaterina, Pittet, Valérie, Godat, Sébastien, Straumann, Alex, Nydegger, Andreas, Vavricka, Stephan R, Moradpour, Darius, Schoepfer, Alain M, Swiss IBD Cohort Study Group, Fraga, Montserrat, Fournier, Nicolas, Safroneeva, Ekaterina, Pittet, Valérie, Godat, Sébastien, Straumann, Alex, Nydegger, Andreas, Vavricka, Stephan R, Moradpour, Darius, Schoepfer, Alain M, and Swiss IBD Cohort Study Group
- Abstract
BACKGROUND AND AIM Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal manifestation of inflammatory bowel disease (IBD). We aimed to assess the prevalence of PSC in the Swiss Inflammatory Bowel Disease Cohort Study, to identify associated risk factors, and to describe the long-term evolution. PATIENTS AND METHODS Data of patients enrolled into the Swiss Inflammatory Bowel Disease Cohort Study were analyzed. Logistic regression modeling was performed to identify risk factors for PSC. RESULTS Among 2744 patients [1188 ulcerative colitis (UC); 1556 Crohn's disease (CD)], 57 had PSC (48 UC-PSC, nine CD-PSC). The prevalence of PSC was higher in UC compared with CD (4.04 vs. 0.58%, P<0.001). We identified the following significant independent risk factors for PSC in patients with UC: male sex [odds ratio (OR) 2.771, P=0.022], pancolitis (OR 2.855, P=0.011), nonsmoker at diagnosis (OR 9.253, P=0.030), and a history of appendicectomy (OR 4.114, P=0.019). During a median follow-up time of 74.8 months, four (7.0%) of PSC patients developed cholangiocarcinoma, six (10.5%) underwent liver transplantation, and five (8.8%) died. Survival of IBD-PSC patients was significantly worse compared with IBD patients without PSC (P=0.001). UC-PSC patients developed significantly more frequently colorectal cancer compared with UC patients without PSC (2/48 vs. 9/1440, P=0.017). CONCLUSION Approximately 4% of UC patients and 0.6% of CD patients had PSC. Male sex, pancolitis, nonsmoker status, and a history of appendicectomy were significantly associated with PSC. PSC is associated with considerable morbidity and mortality in the long term.
- Published
- 2017
5. Systematic Evaluation of Diagnostic Delay in Pediatric Inflammatory Bowel Disease
- Author
-
Schoepfer, Alain M, Vavricka, Stephan, Safroneeva, Ekaterina, Fournier, Nicolas, Manser, Christine, Frei, Pascal, Deltenre, Pierre, Rogler, Gerhard, Straumann, Alex, Ezri, Jessica, Nydegger, Andreas, Braegger, Christian, Schoepfer, Alain M, Vavricka, Stephan, Safroneeva, Ekaterina, Fournier, Nicolas, Manser, Christine, Frei, Pascal, Deltenre, Pierre, Rogler, Gerhard, Straumann, Alex, Ezri, Jessica, Nydegger, Andreas, and Braegger, Christian
- Abstract
We evaluated the diagnostic delay (time from first symptoms to diagnosis) in 100 pediatric patients with Crohn disease (CD) and 75 patients with ulcerative colitis (UC). Median (interquartile range) diagnostic delay in patients with CD was 4 (2-8) (range 0-82) months compared with 2 (1-7) (range 0-52) months in patients with UC (P = 0.003). The time interval from first physician visit to inflammatory bowel disease diagnosis was longer in patients with CD and UC when compared to the time interval from symptom onset to first physician visit (CD: median 3 vs 1 months, P < 0.001; UC: median 2 vs 0 months, P < 0.001). No specific risk factors were identified for the length of diagnostic delay. Measures should be taken to reduce diagnostic delay.
- Published
- 2017
6. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
- Author
-
Vavricka, Stephan R, Gubler, Martin, Gantenbein, Claudine, Spoerri, Muriel, Froehlich, Florian, Seibold, Frank, Protic, Marijana, Michetti, Pierre, Straumann, Alex, Fournier, Nicolas, Juillerat, Pascal, Biedermann, Luc, Zeitz, Jonas, Misselwitz, Benjamin, Scharl, Michael, Heinrich, Henriette, Manser, Christine N, Safroneeva, Ekaterina, Raja Ali, Raja Affendi, Rogler, Gerhard, Schoepfer, Alain M, Greuter, Thomas, Swiss IBD Cohort Study Group, Vavricka, Stephan R, Gubler, Martin, Gantenbein, Claudine, Spoerri, Muriel, Froehlich, Florian, Seibold, Frank, Protic, Marijana, Michetti, Pierre, Straumann, Alex, Fournier, Nicolas, Juillerat, Pascal, Biedermann, Luc, Zeitz, Jonas, Misselwitz, Benjamin, Scharl, Michael, Heinrich, Henriette, Manser, Christine N, Safroneeva, Ekaterina, Raja Ali, Raja Affendi, Rogler, Gerhard, Schoepfer, Alain M, Greuter, Thomas, and Swiss IBD Cohort Study Group
- Published
- 2017
7. Extraintestinal manifestations of pediatric inflammatory bowel disease: prevalence, presentation and anti-TNF treatment
- Author
-
Greuter, Thomas, Bertoldo, Fabio, Rechner, Roman, Straumann, Alex, Biedermann, Luc, Zeitz, Jonas, Misselwitz, Benjamin, Scharl, Michael, Rogler, Gerhard, Safroneeva, Ekaterina, Ali, Raja A R, Braegger, Christian, Heyland, Klaas, Mueller, Pascal, Nydegger, Andreas, Petit, Laetitia-Marie, Schibli, Susanne, Furlano, Raoul I, Spalinger, Johannes, Schäppi, Michela, Zamora, Samuel, Froehlich, Florian, Herzog, Denise, Schoepfer, Alain M, Vavricka, Stephan R, Swiss IBD Cohort Study Group, Greuter, Thomas, Bertoldo, Fabio, Rechner, Roman, Straumann, Alex, Biedermann, Luc, Zeitz, Jonas, Misselwitz, Benjamin, Scharl, Michael, Rogler, Gerhard, Safroneeva, Ekaterina, Ali, Raja A R, Braegger, Christian, Heyland, Klaas, Mueller, Pascal, Nydegger, Andreas, Petit, Laetitia-Marie, Schibli, Susanne, Furlano, Raoul I, Spalinger, Johannes, Schäppi, Michela, Zamora, Samuel, Froehlich, Florian, Herzog, Denise, Schoepfer, Alain M, Vavricka, Stephan R, and Swiss IBD Cohort Study Group
- Abstract
BACKGROUND There is a paucity of data on extraintestinal manifestations (EIM) and their treatment in pediatric patients with inflammatory bowel disease (IBD). METHODS Since 2008, the Pediatric Swiss IBD Cohort Study has collected data on the pediatric IBD population in Switzerland. Data on 329 patients were analyzed retrospectively. RESULTS 55 patients (16.7%) suffered from 1-4 EIM (39 Crohn's disease, 12 ulcerative colitis and 4 IBD-Unclassified (IBD-U) patients). At IBD onset, presence of EIM was more frequent than in the adult population (8.5% vs. 5.0%, p = 0.014). EIM were more frequent in CD when compared to UC/IBD-U (22.5 vs. 10.3%, p = 0.003). The most prevalent EIM were peripheral arthritis (26/329, 7.9%) and aphthous stomatitis (24/329, 7.3%). 27.6% of all EIM appeared before IBD diagnosis. Median time between IBD diagnosis and occurrence of first EIM was 1 month (-37.5-149.0). 31 of the 55 patients (56.4%) were treated with one or more anti-TNF agents. IBD patients with EIM were more likely to be treated with anti-TNF compared to those without (56.4% vs. 35.0%, p = 0.003). Response rates to anti-TNF depended on underlying EIM and were best for peripheral arthritis (61.5%) and uveitis (66.7%). CONCLUSIONS In a cohort of pediatric IBD patients, EIM were frequently encountered. In up to 30%, EIM appeared before IBD diagnosis. Knowledge of these findings might translate into an increased awareness of underlying IBD, thereby decreasing diagnostic delay. Anti- TNF for the treatment of certain EIM is effective although a substantial proportion of new EIM might present despite ongoing anti-TNF therapy.
- Published
- 2017
8. Experts opinion on the practical use of azathioprine and 6-mercaptopurine in inflammatory bowel disease
- Author
-
Mottet, Christian, Schoepfer, Alain M, Juillerat, Pascal, Cosnes, Jacques, Froehlich, Florian, Kessler-Brondolo, Vera, Seibold, Frank, Rogler, Gerhard, Vavricka, Stephan R, Michetti, Pierre, Mottet, Christian, Schoepfer, Alain M, Juillerat, Pascal, Cosnes, Jacques, Froehlich, Florian, Kessler-Brondolo, Vera, Seibold, Frank, Rogler, Gerhard, Vavricka, Stephan R, and Michetti, Pierre
- Abstract
The relevance of azathioprine and 6-mercaptopurine therapy in inflammatory bowel disease, Crohn's disease, and ulcerative colitis, has been challenged in recent publications. In this article, a panel of experts gives advice, based on the relevant literature, on indications and practical use of azathioprine/6-mercaptopurine, prevention, and management of drug adverse reactions and special situations such as vaccination, pregnancy, and lactation.
- Published
- 2016
9. Prevalence and risk factors for therapy escalation in ulcerative colitis in the Swiss IBD Cohort Study
- Author
-
Safroneeva, Ekaterina, Vavricka, Stephan R, Fournier, Nicolas, Straumann, Alex, Rogler, Gerhard, Schoepfer, Alain M, Safroneeva, Ekaterina, Vavricka, Stephan R, Fournier, Nicolas, Straumann, Alex, Rogler, Gerhard, and Schoepfer, Alain M
- Abstract
BACKGROUND: Physicians traditionally treat ulcerative colitis (UC) using a step-up approach. Given the paucity of data, we aimed to assess the cumulative probability of UC-related need for step-up therapy and to identify escalation-associated risk factors. METHODS: Patients with UC enrolled into the Swiss IBD Cohort Study were analyzed. The following steps from the bottom to the top of the therapeutic pyramid were examined: (1) 5-aminosalicylic acid and/or rectal corticosteroids, (2) systemic corticosteroids, (3) immunomodulators (IM) (azathioprine, 6-mercaptopurine, methotrexate), (4) TNF antagonists, (5) calcineurin inhibitors, and (6) colectomy. RESULTS: Data on 996 patients with UC with a median disease duration of 9 years were examined. The point estimates of cumulative use of different treatments at years 1, 5, 10, and 20 after UC diagnosis were 91%, 96%, 96%, and 97%, respectively, for 5-ASA and/or rectal corticosteroids, 63%, 69%, 72%, and 79%, respectively, for systemic corticosteroids, 43%, 57%, 59%, and 64%, respectively, for IM, 15%, 28%, and 35% (up to year 10 only), respectively, for TNF antagonists, 5%, 9%, 11%, and 12%, respectively, for calcineurin inhibitors, 1%, 5%, 9%, and 18%, respectively, for colectomy. The presence of extraintestinal manifestations and extended disease location (at least left-sided colitis) were identified as risk factors for step-up in therapy with systemic corticosteroids, IM, TNF antagonists, calcineurin inhibitors, and surgery. Cigarette smoking at diagnosis was protective against surgery. CONCLUSIONS: The presence of extraintestinal manifestations, left-sided colitis, and extensive colitis/pancolitis at the time of diagnosis were associated with use of systemic corticosteroids, IM, TNF antagonists, calcineurin inhibitors, and colectomy during the disease course.
- Published
- 2015
10. Chronological order of appearance of extraintestinal manifestations relative to the time of ibd diagnosis in the swiss inflammatory bowel disease cohort
- Author
-
Vavricka, Stephan R, Rogler, Gerhard, Gantenbein, Claudine, Spoerri, Muriel, Prinz Vavricka, Mareike, Navarini, Alexander A, French, Lars E, Safroneeva, Ekaterina, Fournier, Nicolas, Straumann, Alex, Froehlich, Florian, Fried, Michael, Michetti, Pierre, Seibold, Frank, Lakatos, Peter L, Peyrin-Biroulet, Laurent, Schoepfer, Alain M, Vavricka, Stephan R, Rogler, Gerhard, Gantenbein, Claudine, Spoerri, Muriel, Prinz Vavricka, Mareike, Navarini, Alexander A, French, Lars E, Safroneeva, Ekaterina, Fournier, Nicolas, Straumann, Alex, Froehlich, Florian, Fried, Michael, Michetti, Pierre, Seibold, Frank, Lakatos, Peter L, Peyrin-Biroulet, Laurent, and Schoepfer, Alain M
- Abstract
BACKGROUND: Data evaluating the chronological order of appearance of extraintestinal manifestations (EIMs) relative to the time of inflammatory bowel disease (IBD) diagnosis is currently lacking. We aimed to assess the type, frequency, and chronological order of appearance of EIMs in patients with IBD. METHODS: Data from the Swiss Inflammatory Bowel Disease Cohort Study were analyzed. RESULTS: The data on 1249 patients were analyzed (49.8% female, median age: 40 [interquartile range, 30-51 yr], 735 [58.8%] with Crohn's disease, 483 [38.7%] with ulcerative colitis, and 31 [2.5%] with indeterminate colitis). A total of 366 patients presented with EIMs (29.3%). Of those, 63.4% presented with 1, 26.5% with 2, 4.9% with 3, 2.5% with 4, and 2.7% with 5 EIMs during their lifetime. Patients presented with the following diseases as first EIMs: peripheral arthritis 70.0%, aphthous stomatitis 21.6%, axial arthropathy/ankylosing spondylitis 16.4%, uveitis 13.7%, erythema nodosum 12.6%, primary sclerosing cholangitis 6.6%, pyoderma gangrenosum 4.9%, and psoriasis 2.7%. In 25.8% of cases, patients presented with their first EIM before IBD was diagnosed (median time 5 mo before IBD diagnosis: range, 0-25 mo), and in 74.2% of cases, the first EIM manifested itself after IBD diagnosis (median: 92 mo; range, 29-183 mo). CONCLUSIONS: In one quarter of patients with IBD, EIMs appeared before the time of IBD diagnosis. Occurrence of EIMs should prompt physicians to look for potential underlying IBD.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.